Ameriprise’s Eli Lilly LLY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q1
– Sell
-4,500
Closed -$3.47M – 4099
2024
Q4
$3.47M Buy
4,500
+1,700
+61% +$1.41M ﹤0.01% 2617
2024
Q3
$2.48M Buy
+2,800
New +$2.52M ﹤0.01% 2799

Other funds holding LLY

Ameriprise's LLY Position: Q3 2026 in Review

Ameriprise increased its Eli Lilly (LLY) stake by 2.6% in Q3 2026, buying an estimated $90.4M and bringing the position to 3,073,253 shares worth $3.56B. The position accounts for 0.72% of the portfolio, ranked #17.

Ameriprise first reported a position in LLY in Q2 2013 and has held it in 54 quarters since. The position peaked at $3.6B in Q2 2026. 4,510 funds tracked by Wall St. Rank hold LLY as of Q3 2026.

  • Ameriprise held 3,073,253 shares of Eli Lilly worth $3.56B as of Q3 2026.
  • Ameriprise bought 76,584 Eli Lilly shares in Q3 2026, an estimated $90.4M.
  • Eli Lilly made up 0.72% of Ameriprise's portfolio in Q3 2026, its #17 holding.
  • Ameriprise first reported a position in Eli Lilly in Q2 2013 and has held it in 54 quarters since.
  • Ameriprise's Eli Lilly position peaked at $3.6B in Q2 2026.
  • 4,510 funds tracked by Wall St. Rank held Eli Lilly as of Q3 2026.

Based on Ameriprise's 13F filing for Q3 2026, filed 16 Nov 2026.